reason report
takeaway sma puls call
bottom line host medacorp puls call april two
kol deep experi treat spinal muscular atrophi sma
patient regard state care patient adapt
challeng pandem consist feedback
manag discuss see note
clinic trial updat see pandem impact
treatment trial enrol sma treater commun find
workaround limit impact patient level kol continu see
novarti zolgensma therapi choic newborn sma patient
provid guidanc dose flexibl patient spinraza
mainten kol interest roch risdiplam primarili
older advanc sma patient receiv zolgensma
difficult spinal anatomi spinal fusion continu
expect spinraza lose share zolgensma risdiplam
kol agre scientif rational combin therapi payer
appetit remain open question
model updat neurosci overal chang
sale estim op spinraza await clariti
dose patient dynam month come reiter
model updat genet medicin updat sma market
model base kol commentari rais zolgensma estim
modestli lower spinraza estim
chang rais pt leav
pt unchang reiter market perform rate
share
compani inform svb leerink llc research
pleas refer page import disclosur price chart analyst certif
kol indic pandem complic sma treatment
patient dose remain larg uninterrupt one kol indic
center patient spinraza zolgensma one sma-posit
newborn screen sinc juli receiv zolgensma gene therapi
expect trend continu regardless spinraza dose continu
well latest patient treat march second kol indic
center patient spinraza zolgensma also newborn go
gene therapi latest patient receiv spinraza april
note workaround facilit sma patient dose pull forward delay
infus time use telehealth avoid on-sit visit etc
regard spinraza kol note patient
mainten subset need infus april affect
avoid put patient risk april spinraza infus
pull forward march kol highlight three key reason mainten
still continu environ infus often done separ site
connect adult hospit oper room get approv
hospit committe sma procedur hurdl
provid use pk guidelin flex spinraza dose schedul minim
impact drug concentr thu allow physician dose broader four-
week window low impact csf drug concentr long next
serial dose adher origin non-delay dose plan said anecdot
one kol heard major institut nearbi delay spinraza infus
month everi month variabl center expect
see impact stretch dose spinraza number like modest
given small fraction patient impact
kol believ activ enrol clinic trial impact
risdiplam advantag agent
ship directli patient home one kol note center limit
visit clinic trial alreadi enrol patient need on-site trial visit
case-by-cas basi kol mention person
famili cancel particip on-going spinraza studi due
concern patient will continu trial kol
expect on-going risdiplam studi see less impact drug ship one
mention abl deliv drug canadian patient cross-bord
logist hurdl call famili often track advers event use
telehealth assess function improv etc notwithstand kol
expect major setback sma clinic trial whole
regard phase devot studi one kol believ prior
evid spinraza higher dose safeti remain open question
prior spinraza clinic trial kol recal dose increas
appear robust effect label dose clean safeti
profil also explain exist dose spinraza reduc
amount well drug reach motor neuron higher dose could
show greater benefit kol explain approv highest dose studi
leav much unknown spinraza profil higher dose kol
note devot site run initi trial amid
pandem may delay start-up remain site
eas use risdiplam clear advantag spinraza kol assum
initi switch slow assum approv risdiplam pdufa date
august kol believ eas use oral risdiplam provid
advantag spinraza howev expect initi switch spinraza
risdiplam slow due uncertainti price reimburs dynam
physician like wait full data jewelfish studi
inform discuss switch families/pati especi children
spinraza alreadi shown clear efficaci accord kol patient
initi switch risdiplam would like achiev suffici
improv upon treatment spinraza and/or older sma patient
advanc diseas physic receiv intrathec inject spinraza
newborn sma patient one-tim therapi zolgensma like
treatment choic high patient interest combin therapi
kol agre burden spinraza famili substanti due recur
hospit visit intrathec administr given choic risdiplam
zolgensma kol believ major patient choos single-infus
gene therapi patient famili believ may option add
either spinraza risdiplam futur year gene therapi treatment
demonstr durabl rational may appli us
develop economi gene therapi may prove cost-prohibit part
world lead patient treatment risdiplam outset
sound scientif rational behind combin therapi still earli day
physician await data jewelfish link kol found valid reason
behind combin therapi sma three soon-to-b approv product
two separ moa zolgensma replac function spinraza
risdiplam modul splice point recent public
univers rochest et al neurolog highlight two patient
previous spinraza switch treatment zolgensma
demonstr gain vocal head control limb strength world
multipl approv therapeut famili may choos pursu treatment two
agent unclear drug provid robust treatment
efficaci specif patient
sma market model chang genet medicin updat model reflect
medacorp kol commentari suggest modest headwind spinraza relat
administr zolgensma newly-diagnos patient broadli
unimped extens risdiplam pdufa date remov month
risdiplam sale sma market model drive addit patient spinraza
total rais full-year zolgensma estim
increment lower full-year spinraza estim
chang increas pt leav pt
rate share market perform fan shareholder-friendli strategi
see attract risk/reward profil earli pipelin worri mid- near-term
consensu number come pressur competit product launch data
readout next year half combin competit environ
earli partner strategi go forward sidelin share current level
month price target per share base discount cash flow methodolog
forecast sale tegsedi royalti spinraza on-going revenu risk-adjust
sale royalti key pipelin agent partner program explicitli model expens
result cash flow assum discount rate consist
compani coverag univers revenu gener approv product
wholly-own independ commerci least one end-market termin
growth rate addit factor ionss net cash balanc valuat
risk view outlook valuat includ major chang price
reimburs coverag unit state europ rare diseas drug tegsedi
spinraza compani key pipelin drug forecast tegsedi also subject
risk better-than-expect market share patisiran tafamidi unmodel
competit entrant use disrupt technolog gene edit risk
includ clinic regulatori disappoint pipelin excess factor
probabl adjust addit sale profit fail match estim ioni
unabl continu secur cash flow gener research develop partnership
line forecast dilut financ may requir order support futur commerci
oper clinic develop pipelin agent
rate share market perform see headlin risk nvs/avexi preclin
data manipul scandal broadli appreci investor remain optimist
zolgensma blockbust see current valuat adequ account robust
royalti stream zolgensma partner asset well compani wholli
own pipelin see crowd competit landscap challeng clinic practic
wet unclear commerci potenti
mucopolysaccharidos type ii mp mp ii clinic meaning data
homozyg famili hypercholesterolemia hofh yet disclos though see
robust clinic scientif rational program cautious optimist
futur data would justifi valu ascrib asset addit compani strong
cash posit potenti non-dilut capit ip licens posit limit balanc
sheet risk due mix risk/reward profil share across program near-
mid-term catalyst consid collect find difficult compellingli argu investor
deploy fresh capit either long short basi present
price target base dcf methodolog forecast risk-
adjust sale risk-adjust royalti
key partner program explicitli model expens result cash flow
assum discount rate consist clinic stage pre-revenu compani
coverag univers termin growth rate addit includ rgnx net cash
balanc valuat
risk view outlook valuat inc includ major chang
price reimburs coverag gene therapi agent unexpect safeti efficaci
signal clinic develop chang regulatori environ forecast subject
unmodel competitor entrant includ gene edit disrupt technolog
could potenti compet share aav-bas therapi develop partner
convers sale royalti forecast includ estim impact certain competit
agent agent fail enter market poorer-than-expect clinic profil
otherwis fail garner share expect could repres materi upsid
estim element compani busi model depend monet
core ip asset chang intellectu properti law enforc compani ip
portfolio could materi impact compani prospect futur cash flow
total cost revenu
research develop
gener administr
sale market
loss incom oper
interest incom licens
total incom expens
loss incom tax
compani report svb leerink equiti research estim
bs mm
cash equival
properti equip net
accru expens current liabil
defer rent net current portion
accumul comprehens loss incom
total liabil stockhold equiti
compani report svb leerink equiti research estim
chang
oper
net amort premium accret discount market debt secur
invest
financ
proce exercis stock option
compani report svb leerink equiti research estim
brand
type event
event trial detail
expect
complet assess cohort
present interim data cohort
present interim data cohort
suprachoroid trial second half
present interim data cohort
suprachoroid trial second half
present interim data cohort
subretin trial second half
interim data readout cohort
interim data readout cohort
eu approv zolgensma
anticip us file bla intrathec
complet pivot strong studi type
submiss ind form batten diseas
program updat neurodegen diseas
svb leerink llc equiti research compani file
research collabor
sale royalti
licens royalti p/w
equiti net loss regulu unc
loss invest
net incom attribut
dilut ep attribut
ownership
compani report svb leerink estim
brand
type event
event trial detail
expect
posit clinic result present
proof concept data readout
proof concept data readout
proof concept data readout
proof concept data readout
svb leerink llc equiti research compani file
